Several of the women in the study were experiencing symptoms associated with fibroids, endometriosis or menstrual complaints when enrolled into the trial. Entering the trial, 8 of the 11 women that completed the study complained of symptoms associated with either endometriosis, uterine fibroids, excessive menstrual bleeding or painful menses. Of these 8 women, 5 reported improvement in their symptoms following the 10 week study. When these assessments were compared to the placebo phase of the trial using a simple symptom severity questionnaire, a solid trend towards statistical significance in symptom improvement was seen, p=0.11. Key symptoms associated with uterine fibroids and endometriosis are, excessive menstrual bleeding and bulk related symptoms for fibroids and menstrual and pelvic pain for endometriosis.
Joseph S. Podolski, President and CEO of Repros noted, "These findings have exceeded our expectations. We eagerly look forward to the higher dose cohorts to see if these findings are enhanced in a dose dependent manner."
The Company plans to issue similar releases as each new cohort completes dosing. Repros believes the study can be completed during the fourth quarter of 2011.
About Repros Therapeutics Inc.Repros Therapeutics focuses on the development of oral small molecule drugs for major unmet medical needs that treat male and female reproductive disorders. The Repros Therapeutics Inc. logo is available at: http://www.globenewswire.com/newsroom/prs/?pkgid=7738 Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including Repros' ability to have the partial hold on Proellex ® lifted, the reliability of preliminary data and interim results, whether a safe and effective dose for Proellex can be determined, and such other risks which are identified in the Company's most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from Repros Therapeutics or at www.sec.gov . Repros disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For more information, please visit the Company's website at http://www.reprosrx.com .
CONTACT: Repros Therapeutics Inc. Joseph Podolski (281) 719-3447 President and Chief Executive Officer